But experts say once-daily dosing versus twice-daily treatment, and a potentially more gut-friendly formulation, may give emraclidine an edge over KarXT, which Bristol Myers Squibb acquired in a $14 billion acquisition of Karuna Therapeutics.‘’
These antipsychotics have a different mechanism of action. They are not D2 antagonists and do not cause weight gain, among other things. We will have to see the clinical experience.
I wish i could try KarXT but I’ve read that the starting price will be $18000-$24000 a year in the US. I don’t think my insurance will cover it…but it’s got to be cheaper than multiple hospitalizations.
It depends on the country you live in. Some countries have something called a “drug exemption regime.” You can ask for special authorization to import it. The problem is the price, of course. Unless you file a complaint with the courts because the health insurance company does not want to cover the cost of the medication.
Personally, I think they will speed up the commercialization of KarXT very quickly, especially in Europe and the United States. They have future competition such as TerXT (within 5 years) and Emraclidine (2 or 3 years).